专利号:EP-0721461-B1 优先权日:1993-09-30 标 题 :Synthesis of 17-(3-pyridyl) steroids 发明人:POTTER GERARD ANDREW; HARDCASTLE IAN ROBERT 权利人:BTG INT LTD 摘要:A method of preparing a 3 beta -hydroxy- or 3 beta -(lower acyloxy) 16,17-ene-17-(3-pyridyl)-substituted steroid, wherein the 3 beta -(lower acyloxy) group of the steroid has from 2 to 4 carbon atoms, which comprises subjecting a 3 beta -hydroxy-16,17-ene-17-iodo or -bromo steroid to a palladium complex-catalysed cross-coupling reaction with a (3-pyridyl)-substituted borane in which the pyridine ring is substituted at the 5-position by an alkyl group of 1 to 4 carbon atoms or is unsubstituted thereat, in a proportion of at least 1.0 equivalent of borane per equivalent of steroid, in an organic liquid which is a solvent for the 3 beta -hydroxy steroidal reaction product, and optionally esterifying the resulting 3 beta -hydroxy steroidal reaction product with an esterifying agent effective to replace the hydroxy group by a said lower acyloxy group, which method comprises (a) carrying out the reaction with not more than 1.2 equivalents of borane per equivalent of steroid or (b) crystallising the product of the cross-coupling reaction from a mixture of acetonitrile and methanol.
专利号:US-2014011992-A1 优先权日:2012-12-20 标 题:Synthesis of abiraterone and related compounds 发明人:PEREZ ENCABO ALFONSO; TURIEL HERNANDEZ JOSE ANGEL; GALLO NIETO FRANCISCO JAVIER; LORENTE BONDE-LARSEN ANTONIO; SANDOVAL RODRIGUEZ CELSO MIGUEL 权利人:CRYSTAL PHARMA SAU 摘要:The present invention relates to processes for obtaining abiraterone and derivatives thereof, such as abiraterone acetate, by means of a Suzuki coupling through a steroid borate of general formula (IV) or a C—C coupling through a steroid hydrazone of general formula (II), as well as to intermediates useful in said processes.
专利号:US-2022118094-A1 优先权日:2019-02-21 标题:Synthesis of biomimetic cell wall structure 发明人:WANG YONG; SHI PENG 权利人:PENN STATE RES FOUND 摘要:The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coated compositions.
专利号:WO-2013030410-A3 优先权日:2011-12-23 标题:Synthesis of abiraterone and related compounds 发明人:PEREZ ENCABO ALFONSO; TURIEL HERNANDEZ JOSE ANGEL; GALLO NIETO FRANCISCO JAVIER; LORENTE BONDE-LARSEN ANTONIO; SANDOVAL RODRIGUEZ CELSO MIGUEL 权利人:CRYSTAL PHARMA SAU 摘要:The present invention relates to processesfor obtaining abirateroneand derivatives thereof, such as abiraterone acetate, by means of a Suzuki coupling through a steroid borate of general formula (IV) or a C-C coupling through a steroid hydrazone of general formula (II), as well as to intermediates useful in said processes.
专利号:US-9650410-B2 优先权日:2013-07-29 标题:Process for the preparation of abiraterone and abiraterone acetate 发明人:LENNA ROBERTO; DI BRISCO RICCARDO 权利人:IND CHIMICA SRL 摘要:The present invention relates to a novel process for the synthesis of abiraterone, and in particular of abiraterone acetate, compound of formula (I) reported below: N O (I) which has pharmacological activity useful for slowing down the progression of prostate cancer at an advanced stage. The process is characterized by an intermediate step wherein DHEA-acetate is triflated using Ar—N(OTf) 2 as the triflation reagent.
专利号:US-8975244-B2 优先权日:2012-07-25 标题:Process and intermediates for the preparation of abiraterone acetate 发明人:MAROM EHUD; RUBNOV SHAI; MIZHIRITSKII MICHAEL 权利人:MAPI PHARMA LTD 摘要:The present invention relates to a process for the synthesis of (3beta)17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates in such processes.
1: Grist E, Attard G. The development of abiraterone acetate for castration-resistant prostate cancer. Urol Oncol. 2015 Jun;33(6):289-294. doi: 10.1016/j.urolonc.2015.03.021. Review. doi: 10.1016/j.clgc.2014.10.006. Epub 2014 Nov 7. Review. Review. doi: 10.2147/RRU.S29003. eCollection 2014. Review. 5: Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014 Oct;14(10):1135-40. doi: 10.1586/14737140.2014.949677. Epub 2014 Aug 19. Review. doi: 10.1111/ajco.12264. Epub 2014 Aug 17. Review. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22. Review. 8: Boissier E, Loriot Y, Vignot S, Massard C. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French. Review.
合成参考文献
参考文献:10.1007/s11912-012-0285-1 摘要:Al-Asaaed S, Winquist E. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer. Curr Oncol Rep. 2013 Apr;15(2):113–8. doi: 10.1007/s11912-012-0285-1. 参考文献:10.1007/s13277-014-2145-0 摘要:Francini E, Roviello G. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients Response should be found in prostate cancer tissue. Tumour Biol. 2014 Aug;35(8):7391–2. doi: 10.1007/s13277-014-2145-0. 参考文献:10.1186/s12885-018-4401-y 摘要:Uemura K, Miyoshi Y, Kawahara T, Ryosuke J, Yamashita D, Yoneyama S, Yokomizo Y, Kobayashi K, Kishida T, Yao M, Uemura H. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. BMC Cancer. 2018 May 02;18(1):501. 参考文献:10.1111/jcpt.12693 摘要:Marin S, Querol R, Campins L, Miarons M, Font A, Lianes P. Long-term abiraterone withdrawal syndrome. J Clin Pharm Ther. 2018 Oct;43(5):714–6. doi: 10.1111/jcpt.12693. 参考文献:10.1016/j.clgc.2019.05.026 摘要:van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clin Genitourin Cancer. 2019 Oct;17(5):e893–6. doi: 10.1016/j.clgc.2019.05.026.